FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2497895663> ?p ?o ?g. }

• W2497895663 abstract "Abstract Abstract 1644 Introduction: Previous phase 2 single agent trials with the immunomodulatory agent, lenalidomide, in patients with relapsed or refractory HL demonstrated overall response rates (ORR) of 14–29%, with a median duration of response of 6 months. Likewise, a single agent trial utilizing the orally available HDAC inhibitor, panobinostat, in 127 patients with relapsed/refractory HL after prior autologous stem cell transplant (ASCT) demonstrated an ORR of 27% with a median duration of response of 6.9 months. Based on the encouraging single agent activity of these agents and in vitro synergy of combined panobinostat and lenalidomide in myeloma cell lines, we are conducting a phase I/II trial to determine the dose limiting toxicity (DLT), maximum tolerated dose (MTD), and overall response rate (ORR) with this combination and results of the phase I study are presented. Methods: Patients with relapsed or refractory classical HL (cHL) or lymphocyte predominant HL (LP HL) after at least one prior therapy are eligibile. Measurable disease ≥1 cm in at least one dimension, ejection fraction ≥45%, ECOG PS 0–2, QTc on ECG ≤ 450 msec, ANC ≥1200/mm3, platelets ≥100,000/mm3, AST/ALT ≤ 2.5 × the upper limit of normal (ULN), bilirubin ≤ 1.5 × ULN, and creatinine clearance ≥60 ml/min are required at study entry. Prior ASCT, lenalidomide, and panobinostat are permitted. In the phase I trial, escalating doses of panobinostat (15 or 20 mg) days 1, 3, and 5 weekly are combined with lenalidomide 25 mg days 1–21 utilizing a cohorts of 3 design. DLT is defined during cycle 1 and includes grade 4 neutropenia or thrombocytopenia, grade 4 infection, grade 3 infection for > 7 days, treatment delays > 14 days, and other grade 3–4 non-hematologic toxicity. Six patients will be enrolled at the MTD to ensure patient safety prior to phase 2 enrollment. Twenty-eight days defines a cycle and patients may remain on therapy until disease progression or unacceptable toxicity. Response is assessed after cycles 2, 6, and every 4 cycles thereafter by International Harmonization Criteria (Cheson, JCO 2007). Results: Seven patients (6 males) with cHL (n=6) and LP HL (n=1) and a median age of 31 (range 24–72) have been enrolled. Patients received a median of 3 prior therapies (range 3–5), 1 patient received prior radiotherapy, 3 patients were refractory to their most recent therapy, 3 patients had prior ASCT, 6 patients had received prior brentuximab vedotin, and no patients had prior lenalidomide or panobinostat. Other characteristics included stage III-IV disease in 100% (57% stage IV), bulky adenopathy ≥5 cm in 14%, and bone marrow involvement in 14%. Seven patients have completed one or more cycles of therapy (median 3, range 1–4) with either 15 mg (n=3) or 20 mg (n=4) of panobinostat + 25 mg lenalidomide. Four patients discontinued therapy for progressive disease (PD) after 4 cycles (n=3) and 1 cycle (n=1), respectively. Three patients continue to receive protocol treatment, all receiving panobinostat 20 mg days 1, 3, and 5 weekly. No DLTs have been observed. Grade 3–4 events included neutropenia (43%), lymphopenia (29%), thrombocytopenia (29%), and hypophosphatemia (29%). No QTc prolongation has been observed. Dose reductions from 15 mg panobinostat days 1, 3, and 5 weekly + lenalidomide 25 mg to 15 mg panobinostat days 1, 3, and 5 weeks 1 and 3 only + 20 mg lenalidomide were required in 2 patients for grade 3–4 neutropenia during cycles 3 and 4. ORR is 33% in 6 evaluable patients with a complete response in 1 patient with cHL and partial response in 1 patient with LP HL. One patient has not yet undergone restaging scans. Conclusions: Combined panobinostat and lenalidomide appears to be well tolerated in patients with relapsed/refractory HL without dose limiting myelosuppression, cardiac toxicity, QTc prolongation, or other grade 3–4 non-hematologic toxicity. Study accrual continues, 2 additional patients will be added to the highest dose level (panobinostat 20 mg days 1, 3, and 5 weekly for 4 weeks + lenalidomide 25 mg days 1–21) to complete the phase I trial and will be followed by anticipated enrollment of a maximum of 25 patients to a two-stage phase 2 trial targeting an ORR of 30% or higher. Disclosures: Blum: Celgene: Research Funding; Novartis: Research Funding. Off Label Use: Panobinostat and lenalidomide are not approved for the treatment of HL." @default.
• W2497895663 created "2016-08-23" @default.
• W2497895663 creator A5007847102 @default.
• W2497895663 creator A5010839952 @default.
• W2497895663 creator A5015361329 @default.
• W2497895663 creator A5016323798 @default.
• W2497895663 creator A5029524605 @default.
• W2497895663 creator A5056946123 @default.
• W2497895663 creator A5072835425 @default.
• W2497895663 creator A5078397650 @default.
• W2497895663 creator A5088169139 @default.
• W2497895663 date "2012-11-16" @default.
• W2497895663 modified "2023-09-30" @default.
• W2497895663 title "A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL)" @default.
• W2497895663 doi "https://doi.org/10.1182/blood.v120.21.1644.1644" @default.
• W2497895663 hasPublicationYear "2012" @default.
• W2497895663 type Work @default.
• W2497895663 sameAs 2497895663 @default.
• W2497895663 citedByCount "5" @default.
• W2497895663 countsByYear W24978956632014 @default.
• W2497895663 countsByYear W24978956632015 @default.
• W2497895663 countsByYear W24978956632017 @default.
• W2497895663 countsByYear W24978956632018 @default.
• W2497895663 countsByYear W24978956632020 @default.
• W2497895663 crossrefType "journal-article" @default.
• W2497895663 hasAuthorship W2497895663A5007847102 @default.
• W2497895663 hasAuthorship W2497895663A5010839952 @default.
• W2497895663 hasAuthorship W2497895663A5015361329 @default.
• W2497895663 hasAuthorship W2497895663A5016323798 @default.
• W2497895663 hasAuthorship W2497895663A5029524605 @default.
• W2497895663 hasAuthorship W2497895663A5056946123 @default.
• W2497895663 hasAuthorship W2497895663A5072835425 @default.
• W2497895663 hasAuthorship W2497895663A5078397650 @default.
• W2497895663 hasAuthorship W2497895663A5088169139 @default.
• W2497895663 hasConcept C104317684 @default.
• W2497895663 hasConcept C121332964 @default.
• W2497895663 hasConcept C126322002 @default.
• W2497895663 hasConcept C141071460 @default.
• W2497895663 hasConcept C142424586 @default.
• W2497895663 hasConcept C143998085 @default.
• W2497895663 hasConcept C185592680 @default.
• W2497895663 hasConcept C197934379 @default.
• W2497895663 hasConcept C2776063141 @default.
• W2497895663 hasConcept C2776364478 @default.
• W2497895663 hasConcept C2777063308 @default.
• W2497895663 hasConcept C2778305200 @default.
• W2497895663 hasConcept C2778375690 @default.
• W2497895663 hasConcept C2778850193 @default.
• W2497895663 hasConcept C2780225316 @default.
• W2497895663 hasConcept C29730261 @default.
• W2497895663 hasConcept C31760486 @default.
• W2497895663 hasConcept C55493867 @default.
• W2497895663 hasConcept C64927066 @default.
• W2497895663 hasConcept C71924100 @default.
• W2497895663 hasConcept C87355193 @default.
• W2497895663 hasConcept C90924648 @default.
• W2497895663 hasConceptScore W2497895663C104317684 @default.
• W2497895663 hasConceptScore W2497895663C121332964 @default.
• W2497895663 hasConceptScore W2497895663C126322002 @default.
• W2497895663 hasConceptScore W2497895663C141071460 @default.
• W2497895663 hasConceptScore W2497895663C142424586 @default.
• W2497895663 hasConceptScore W2497895663C143998085 @default.
• W2497895663 hasConceptScore W2497895663C185592680 @default.
• W2497895663 hasConceptScore W2497895663C197934379 @default.
• W2497895663 hasConceptScore W2497895663C2776063141 @default.
• W2497895663 hasConceptScore W2497895663C2776364478 @default.
• W2497895663 hasConceptScore W2497895663C2777063308 @default.
• W2497895663 hasConceptScore W2497895663C2778305200 @default.
• W2497895663 hasConceptScore W2497895663C2778375690 @default.
• W2497895663 hasConceptScore W2497895663C2778850193 @default.
• W2497895663 hasConceptScore W2497895663C2780225316 @default.
• W2497895663 hasConceptScore W2497895663C29730261 @default.
• W2497895663 hasConceptScore W2497895663C31760486 @default.
• W2497895663 hasConceptScore W2497895663C55493867 @default.
• W2497895663 hasConceptScore W2497895663C64927066 @default.
• W2497895663 hasConceptScore W2497895663C71924100 @default.
• W2497895663 hasConceptScore W2497895663C87355193 @default.
• W2497895663 hasConceptScore W2497895663C90924648 @default.
• W2497895663 hasLocation W24978956631 @default.
• W2497895663 hasOpenAccess W2497895663 @default.
• W2497895663 hasPrimaryLocation W24978956631 @default.
• W2497895663 hasRelatedWork W2017144533 @default.
• W2497895663 hasRelatedWork W2098002594 @default.
• W2497895663 hasRelatedWork W2155256323 @default.
• W2497895663 hasRelatedWork W2168713493 @default.
• W2497895663 hasRelatedWork W2474589366 @default.
• W2497895663 hasRelatedWork W2502524943 @default.
• W2497895663 hasRelatedWork W2521550987 @default.
• W2497895663 hasRelatedWork W2537548903 @default.
• W2497895663 hasRelatedWork W2557591402 @default.
• W2497895663 hasRelatedWork W2559382927 @default.
• W2497895663 hasRelatedWork W2567429037 @default.
• W2497895663 hasRelatedWork W2568433166 @default.
• W2497895663 hasRelatedWork W2572116053 @default.
• W2497895663 hasRelatedWork W2590111115 @default.
• W2497895663 hasRelatedWork W2620029856 @default.
• W2497895663 hasRelatedWork W2980007807 @default.
• W2497895663 hasRelatedWork W2980073076 @default.
• W2497895663 hasRelatedWork W2980140263 @default.
• W2497895663 hasRelatedWork W3095175361 @default.

• next